Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of nebulized recombinant human interferon alfa-1b in children with RSV lower respiratory tract infection
CTR20201509Phase 3Active
- Sponsor
- 三元基因
- Start
- Feb 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human interferon alpha-1b in respiratory syncytial virus disease (RSV), respiratory syncytial virus pneumonia, respiratory syncytial virus bronchiolitis, sponsored by 三元基因. Started Feb 2021; status: active.
02
Drugs
recombinant human interferon alpha-1b
03
Conditions
respiratory syncytial virus disease (RSV)respiratory syncytial virus pneumoniarespiratory syncytial virus bronchiolitis
Beyond the preview
Go deeper on CTR20201509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201509.